News & Updates

Microbiome-derived deoxycholic acid (DCA) worsens portal hypertension by boosting TPH1-dependent 5-hydroxytryptamine (5-HT) biosynthesis, which activates portal vein smooth muscle cell contraction via HTR1A-GIRK3 signalling, a study has found.

Results from the Italian RISP* trial presented at WCLC 2026 show improvement in smoking cessation rates following treatment with cytisine, a partial agonist of α4β2nicotinic acetylcholine receptors.

Arginine therapy is no better than placebo in terms of improving outcomes in children and young adults with sickle cell disease (SCD) who are experiencing acute pain episodes, according to the phase III STArT trial.

In the first-line treatment of patients with advanced HER2-mutant non-small cell lung cancer (NSCLC), trastuzumab deruxtecan (T-DXd) monotherapy confers a 6-month improvement in progression-free survival (PFS) compared with pembrolizumab plus chemotherapy, as shown in the phase III DESTINY-Lung04 trial.

Patient-reported outcomes among young adults with persistent knee problems after anterior cruciate ligament reconstruction (ACLR) improve with physiotherapist-supervised exercise therapy plus education compared with a single education session and self-directed exercise resource, according to a study.

A generalist-led care, the Integrated General Hospital (IGH) care model, demonstrates a numerically lower number of deaths and clinical outcomes comparable to a specialist-led care, the usual care model, as shown in a Singapore study. Patient care experiences with IGH are also positive.

The American College of Rheumatology/European Alliance of Associations for Rheumatology (ACR/EULAR) Total Improvement Score (TIS) may be used in research autoimmune inflammatory myopathies (AIM), according to a study.

Patients with chronic hepatitis B (CHB) infection who consume high levels of alcohol are at increased risk of hepatocellular carcinoma (HCC), as suggested in a retrospective study from China.

A report from Children’s Oncology Group (COG) AALL1731 study showed that paediatric patients with standard-risk (SR) B-cell acute lymphoblastic leukaemia (B-ALL) with undetectable minimal residual disease (MRD) at end of induction (EOI) by flow cytometry (FC) but not high-throughput sequencing (HTS) had inferior outcomes on chemotherapy alone, which were partially but not entirely mitigated by blinatumomab. In addition, outcomes of chemotherapy-only treatment among patients with MRD by HTS were not superior to those of patients with detectable MRD.